Infectivity of blood products containing cytomegalovirus DNA: results of a lookback study in nonimmunocompromised patients

Transfusion

Volumn 57, Issue 7, 2017, Pages 1691-1698

  Ziemann, Malte ^a   Juhl, David ^a   Brockmann, Christian ^a   Görg, Siegfried ^a   Hennig, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; VIRUS ANTIBODY; VIRUS DNA;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD COMPONENT; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NONHUMAN; PASSIVE IMMUNIZATION; RECIPIENT; SEROCONVERSION; VERY ELDERLY; BLOOD; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BLOOD DONORS; CYTOMEGALOVIRUS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED;

EID: 85017176457     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14105     Document Type: Article

References (25)

1. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 2008;197:65-73.
2. Kääriäinen L, Klemola E, Paloheimo J. Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. Br Med J 1966;1:1270-2.
3. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005;19:181-99.
4. Ziemann M, Hennig H. Prevention of transfusion-transmitted cytomegalovirus infections: which is the optimal strategy? Transfus Med Hemother 2014;41:40-4.
5. Simanek AM, Dowd JB, Pawelec G, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One 2011;6:e16103.
6. Arens R, Remmerswaal EBM, Bosch JA, et al. 5(th) International Workshop on CMV and Immunosenescence—a shadow of cytomegalovirus infection on immunological memory. Eur J Immunol 2015;45:954-7.
7. Barnes LL, Capuano AW, Aiello AE, et al. Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis 2015;211:230-7.
8. AABB, Clinical Transfusion Medicine Committee, Heddle NM, Boeckh M, et al. AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. Transfusion 2016;56:1581-7.
9. Vollmer T, Knabbe C, Dreier J. Systematic evaluation of different nucleic acid amplification assays for cytomegalovirus detection: feasibility of blood donor screening. J Clin Microbiol 2015;53:3219-25.
10. Ziemann M, Krueger S, Maier AB, et al. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007;47:1972-83.
11. Ziemann M, Unmack A, Steppat D, et al. The natural course of primary cytomegalovirus infection in blood donors. Vox Sang 2010;99:24-33.
12. Ziemann M, Heuft HG, Frank K, et al. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 2013;53:1088-94.
13. Ziemann M, Juhl D, Görg S, et al. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion 2013;53:2183-9.
14. Nankervis GA. Cytomegalovirus infections in the blood recipient. Yale J Biol Med 1976;49:13-5.
15. Tolpin MD, Stewart JA, Warren D, et al. Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis. J Pediatr 1985;107:953-6.
16. Thiele T, Krüger W, Zimmermann K, et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011;51:2620-6.
17. Wu Y, Zou S, Cable R, et al. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010;50:776-86.
18. Drew WL, Tegtmeier G, Alter HJ, et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003;43:309-13.
19. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004;125:107-16.
20. Josephson CD, Caliendo AM, Easley KA, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr 2014;168:1054-62.
21. Delaney M, Mayock D, Knezevic A, et al. Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy. Transfusion 2016;56:1945-50.
22. Kekre N, Tokessy M, Mallick R, et al. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant 2013;19:1719-24.
23. Nash T, Hoffmann S, Butch S, et al. Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion 2012;52:2270-2.
24. Hall S, Danby R, Osman H, et al. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experience. Transfus Med 2015;25:418-23.
25. Hecker M, Qiu D, Marquardt K, et al. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang 2004;86:41-4.